Evaluation of Ocular Surface Inflammatory Mediators and Ocular Surface Metrology Effected by Lotemax

Trial Profile

Evaluation of Ocular Surface Inflammatory Mediators and Ocular Surface Metrology Effected by Lotemax

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Oct 2015

At a glance

  • Drugs Loteprednol etabonate (Primary)
  • Indications Sjogren's syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Oct 2015 Primary end points has been changed as reported by ClinicalTrials.gov record.
    • 30 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top